Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 308

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 308
---
, prepaid and other current assets, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Cash equivalents, marketable securities, and the preferred stock warrants liability are recorded at fair value on a recurring basis. Equity investments without a readily determinable fair value are recorded at cost and adjusted to fair value based on observable price changes in orderly transactions for identical or similar investment of the same issuer.None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):Fair Value Measurements at Reporting DateTotalLevel 1Level 2Level 3At June 30, 2025:Cash equivalentsMoney market funds$35,609 $35,609 $— $— Corporate debt securities1,550 — 1,550 — Total cash equivalents measured at fair value$37,159 $35,609 $1,550 $— Marketable securitiesU.S. treasury securities$51,902 $51,902 $— $— Commercial paper50,548 — 50,548 — Corporate debt securities49,005 — 49,005 — U.S. government agency securities18,444 — 18,444 — Asset-backed securities2,012 — 2,012 — Total marketable securities measured at fair value$171,911 $51,902 $120,009 $— At December 31, 2024:Cash equivalentsMoney market funds$17,693 $17,693 $— $— U.S. government securities999 — 999 — U.S. treasury securities997 997 — — Total cash equivalents measured at fair value$19,689 $18,690 $999 $— Marketable securitiesCommercial paper$58,823 $— $58,823 $— U.S. treasury securities46,309 46,309 — — Corporate debt securities43,669 — 43,669 — U.S. government agency securities40,071 — 40,071 — Total marketable securities measured at fair value$188,872 $46,309 $142,563 $— 

15

The following table presents the amortized cost and estimated fair market